Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes

Drug Metabolism and Disposition

Volumn 28, Issue 1, 2000, Pages 73-78

  Kuriya, Shin Ichiro ^b   Ohmori, Shigeru ^a   Hino, Mayuko ^b   Ishii, Itsuko ^b   Nakamura, Hiroyoshi ^b   Senda, Chiaki ^b   Igarashi, Takashi ^b   Kiuchi, Masahiro ^b   Kitada, Mitsukazu ^b  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; PIMOBENDAN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CARDIOTONIC AGENTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROTEIN ISOFORMS; PYRIDAZINES; VASODILATOR AGENTS;

EID: 0033970426     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Brankhorst D, Van der Leyen H, Meyer W, Nigbur R, Schmidt-Schmacher C and Scholz H (1989) Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG2112 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 339:575-583.
3. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch Biochem Biophys 311:437-442.
4. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M and Ishizaki T (1993) Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase in human liver microsomes. Eur J Clin Pharmacol 44:559-562.
5. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobitica 28:1167-1202.
6. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
7. Fitton A and Brogden RN (1994) Pimobendan, a review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 4:417-441.
8. Fraker KD, Van Eyk J and Solaro RJ (1997) Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG212CL, in myofilaments from human ventricle. Mol Cell Biochem 176:83-88.
9. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circ Res 63:911-922.
10. Goldstein JA, Faletto MB, Romkessparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
11. Greenlee WF and Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: Induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlordibenzo-p-oxin. J Pharmacol Exp Ther 205:596-605.
12. Hagemeijer F (1993) Calcium sensitization with pimobendan: Pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 14:551-566.
13. Hayashi S, Noshiro M and Okuda K (1986) Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes. J Biochem 99:1753-1763.
14. Kitada M, Kato T, Ohmori S, Kamataki T, Itahashi K, Guengerich FP, Rikihisa T and Kanakubo Y (1992) Immunochemical characterization and toxicological significance of P450HFLb purified from human fetal liver homogenates. Biochim Biophys Acta 1117:301-305.
15. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933.
16. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
17. Miners JO, Smith KJ, Robson RA, Mcmanus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 37:1137-1144.
18. Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S and Kitada M (1998) Prediction of drug-drug interaction of zonisamide metabolism in human from in vitro data. Eur J Clin Pharmacol 54:177-183.
19. Nash T (1953) Colorimetric estimation of formaldehyde by means of the Hontsch reaction. Biochem J 55:416-421.
20. Nelson DR, Koymans L, Kamataki T, Stageman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Neben DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
21. Ohmori S, Ishii I, Kuriya S, Taniguchi T, Rikihisa T, Hirose S, Kanakubo Y and Kitada M (1993) Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 21:358-363.
22. Ohmori S, Kudo S, Nakasa H, Horie T and Kitada M (1994) Purification and characterization of cytochrome P450 3A enzyme from hepatic microsomes of doguera baboons. Biol Pharm Bull 17:1584-1588.
23. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylations by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
25. Relling MV, Nemec J, Shuetz EG, Schuetz JD Gonzalez FJ and Korzekwa KR (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358.
26. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A and Matsubara T (1995) A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: Purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319:372-382.
27. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, Torre RD and Davis DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450Ia2 in man. Br J Clin Pharmacol 29:651-663.
28. Shimada T, Yamazaki H, Mimura M, Inui Y and Gengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
29. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
30. Tassaneeyakul W, Birkett DJ, Veronese ME, Mcmanus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993a) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
31. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ and Miners JO (1993b) Validation of 4-nitrophenol as an in vitro probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975-1981.
32. Tassaneeyakul W, Veronese ME, Birkett DJ and Miners JO (1993c) High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J Chromatogr 616:73-78.
33. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo, Duan SX, Harmatz JS and Shader RI (1994) Inhibition desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
34. Walkins PB, Wrighton SA, Maurel P, Schuetz EG, Menzez-Picon G, Parker GA and Guzelian PS (1985) Identification of inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.
35. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ and Korzekwa KR (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290:160-166.
36. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
37. Yun CH, Shimada T and Guengerich FP (1991) Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol Pharmacol 40:679-685.